Market Research Logo

Acute Ischemic Stroke - Pipeline Review, H2 2016

Acute Ischemic Stroke - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Acute Ischemic Stroke - Pipeline Review, H2 2016’, provides an overview of the Acute Ischemic Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Ischemic Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Ischemic Stroke and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Acute Ischemic Stroke
    • The report reviews pipeline therapeutics for Acute Ischemic Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Acute Ischemic Stroke therapeutics and enlists all their major and minor projects
    • The report assesses Acute Ischemic Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Acute Ischemic Stroke
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Acute Ischemic Stroke
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Acute Ischemic Stroke pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Acute Ischemic Stroke Overview
    Therapeutics Development
    Pipeline Products for Acute Ischemic Stroke - Overview
    Acute Ischemic Stroke - Therapeutics under Development by Companies
    Acute Ischemic Stroke - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Acute Ischemic Stroke - Products under Development by Companies
    Acute Ischemic Stroke - Companies Involved in Therapeutics Development
    AB Science SA
    AstraZeneca Plc
    Biogen Inc
    D-Pharm Ltd.
    Daiichi Sankyo Company, Limited
    DiaMedica Inc.
    Digna Biotech, S.L.
    Glucox Biotech AB
    Jeil Pharmaceutical Co., Ltd.
    Lumosa Therapeutics Co., Ltd.
    Mitsubishi Tanabe Pharma Corporation
    Pharmicell Co., Ltd.
    PhytoHealth Corporation
    Remedy Pharmaceuticals, Inc.
    Saneron CCEL Therapeutics, Inc.
    Simcere Pharmaceutical Group
    Stemedica Cell Technologies, Inc.
    Acute Ischemic Stroke - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    3K3A-APC - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AB-022 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ApTLR-4FT - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellgram-IS - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DB-017 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DM-199 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DS-1040 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    glyburide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HBI-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HBN-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JPI-289 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LT-3001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    masitinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MP-124 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    natalizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Neu-2000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PHN-014 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Rejuveinix - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SIM-071201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Neurological and Cardiovascular Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    THR-18 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ticagrelor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TMS-007 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Acute Ischemic Stroke - Dormant Projects
    Acute Ischemic Stroke - Discontinued Products
    Acute Ischemic Stroke - Product Development Milestones
    Featured News & Press Releases
    Sep 12, 2016: DiaMedica Announces Regulatory Clearance to Initiate Bridging Clinical Trial for DM199
    Jun 14, 2016: DiaMedica Announces U.S. Composition of Matter Patent for DM199
    Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia
    Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial
    Nov 04, 2015: DiaMedica Provides Corporate Update
    Oct 09, 2015: Remedy Pharmaceuticals’ Drug CIRARA™ Cut Death Rates from Severe Stroke by More Than Half
    Sep 29, 2015: Remedy Pharmaceuticals Announces Phase 2 Severe Stroke Study Results to Be Presented at Neurocritical Care Annual Meeting
    Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference
    Dec 18, 2014: D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA
    Nov 04, 2014: D-Pharm Reports First Results From its Phase 2 Clinical Study of THR-18 In Acute Stroke Patients Treated with tPA
    Aug 19, 2014: US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA
    Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA
    Apr 22, 2014: ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures
    Mar 04, 2014: D-Pharm reports the successful interim analysis of its Phase 2 clinical study of THR-18 in acute stroke patients
    Jan 21, 2014: D-Pharm completes recruitment of patients into the first dosage tier of its Phase 2 study with THR-18 in acute stroke patients treated with tPA
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Acute Ischemic Stroke, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Acute Ischemic Stroke - Pipeline by AB Science SA, H2 2016
    Acute Ischemic Stroke - Pipeline by AstraZeneca Plc, H2 2016
    Acute Ischemic Stroke - Pipeline by Biogen Inc, H2 2016
    Acute Ischemic Stroke - Pipeline by D-Pharm Ltd., H2 2016
    Acute Ischemic Stroke - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
    Acute Ischemic Stroke - Pipeline by DiaMedica Inc., H2 2016
    Acute Ischemic Stroke - Pipeline by Digna Biotech, S.L., H2 2016
    Acute Ischemic Stroke - Pipeline by Glucox Biotech AB, H2 2016
    Acute Ischemic Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
    Acute Ischemic Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H2 2016
    Acute Ischemic Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
    Acute Ischemic Stroke - Pipeline by Pharmicell Co., Ltd., H2 2016
    Acute Ischemic Stroke - Pipeline by PhytoHealth Corporation, H2 2016
    Acute Ischemic Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H2 2016
    Acute Ischemic Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2016
    Acute Ischemic Stroke - Pipeline by Simcere Pharmaceutical Group, H2 2016
    Acute Ischemic Stroke - Pipeline by Stemedica Cell Technologies, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Acute Ischemic Stroke - Dormant Projects, H2 2016
    Acute Ischemic Stroke - Dormant Projects (Contd..1), H2 2016
    Acute Ischemic Stroke - Dormant Projects (Contd..2), H2 2016
    Acute Ischemic Stroke - Discontinued Products, H2 2016
    Acute Ischemic Stroke - Discontinued Products (Contd..1), H2 2016
    List of Figures
    Number of Products under Development for Acute Ischemic Stroke, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report